FDA grants de novo approval to Neuromod’s tinnitus device

Global News

The FDA has granted de novo approval to Neuromod’s Lenire device, which includes Bluetooth headphones, a handheld controller and the Tonguetip intraoral device to treat tinnitus.

The device is non-invasive and the company claims it is the first of its kind to receive this sort of approval from the FDA. The device combines acoustic and electrical intraoral stimulation to provide relief to patients suffering with tinnitus, which is a complex neurological condition.

The therapy includes three elements: Bluetooth headphones to deliver customised sound stimuli to the auditory nerve; a lightweight, handheld controller, which lets patients adjust the length and intensity of treatment; and an intraoral device known as Tonguetip, which provides gentle electrical stimulation to the surface of the tongue to activate the patient’s nerves.

The sounds and tongue stimulation are intended to work alongside each other to reduce the severity of the patient’s symptoms. The device is the first non-invasive bimodal neuromodulation tinnitus treatment device, which has appeared to relieve tinnitus throughout three large-scale clinical trials.

Neuromod Devices founder and CEO, Ross O’Neill commented: “Lenire’s approval not only means that millions of Americans living with tinnitus can get the treatment they need but further validates over a decade of R&D that resulted in a safe solution that provides relief for tinnitus patients. […] Lenire is the first bimodal neuromodulation device to go through the rigours of the FDA’s de novo process. […] For patients that are at least moderately impacted by their tinnitus, Lenire has now been shown to be more effective than sound therapy, which is one of the current clinical standards of treatment.”

Contaminated cough syrup leads to WHO Medical Product Alert

The WHO has shared a medical product alert for an additional contaminated cough syrup medicine identified in Africa.

New open innovation hub opened by Astellas for tumour microenvironment research

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended to open in October 2023.

Jemperli by GSK approved to treat endometrial cancer

GSK has announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (DMMR) or microsatellite instability-high (MSI-H).

Alzheimer’s disease drug Leqembi given full approval by FDA

Japanese Eisai and US-based biotechnology company Biogen have announced that the FDA has given their Alzheimer’s disease drug Leqembi (lecanemab-irmb) full approval through the approval of a supplemental biologics license application.

First over the counter contraceptive pill approved by FDA

FDA has announced that it has approved the Opill (norgestrel) tablet for non-prescription use to prevent pregnancy.

Contaminated cough syrup leads to WHO Medical Product Alert

New open innovation hub opened by Astellas for tumour microenvironment research

Jemperli by GSK approved to treat endometrial cancer

Alzheimer’s disease drug Leqembi given full approval by FDA

First over the counter contraceptive pill approved by FDA

Pharmafocus

Categories

Social Footprints